Your browser doesn't support javascript.
Omicron infection enhances Delta antibody immunity in vaccinated persons.
Khan, Khadija; Karim, Farina; Cele, Sandile; Reedoy, Kajal; San, James Emmanuel; Lustig, Gila; Tegally, Houriiyah; Rosenberg, Yuval; Bernstein, Mallory; Jule, Zesuliwe; Ganga, Yashica; Ngcobo, Nokuthula; Mazibuko, Matilda; Mthabela, Ntombifuthi; Mhlane, Zoey; Mbatha, Nikiwe; Miya, Yoliswa; Giandhari, Jennifer; Ramphal, Yajna; Naidoo, Taryn; Sivro, Aida; Samsunder, Natasha; Kharsany, Ayesha B M; Amoako, Daniel; Bhiman, Jinal N; Manickchund, Nithendra; Abdool Karim, Quarraisha; Magula, Nombulelo; Abdool Karim, Salim S; Gray, Glenda; Hanekom, Willem; von Gottberg, Anne; Milo, Ron; Gosnell, Bernadett I; Lessells, Richard J; Moore, Penny L; de Oliveira, Tulio; Moosa, Mahomed-Yunus S; Sigal, Alex.
  • Khan K; Africa Health Research Institute, Durban, South Africa.
  • Karim F; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Cele S; Africa Health Research Institute, Durban, South Africa.
  • Reedoy K; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • San JE; Africa Health Research Institute, Durban, South Africa.
  • Lustig G; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Tegally H; Africa Health Research Institute, Durban, South Africa.
  • Rosenberg Y; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Bernstein M; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Jule Z; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Ganga Y; Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
  • Ngcobo N; Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Mazibuko M; Africa Health Research Institute, Durban, South Africa.
  • Mthabela N; Africa Health Research Institute, Durban, South Africa.
  • Mhlane Z; Africa Health Research Institute, Durban, South Africa.
  • Mbatha N; Africa Health Research Institute, Durban, South Africa.
  • Miya Y; Africa Health Research Institute, Durban, South Africa.
  • Giandhari J; Africa Health Research Institute, Durban, South Africa.
  • Ramphal Y; Africa Health Research Institute, Durban, South Africa.
  • Naidoo T; Africa Health Research Institute, Durban, South Africa.
  • Sivro A; Africa Health Research Institute, Durban, South Africa.
  • Samsunder N; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Kharsany ABM; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Amoako D; Africa Health Research Institute, Durban, South Africa.
  • Bhiman JN; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Manickchund N; Department of Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa.
  • Abdool Karim Q; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Magula N; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Abdool Karim SS; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Gray G; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Hanekom W; Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • von Gottberg A; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Milo R; Department of Internal Medicine, Nelson R. Mandela School of Medicine, University of Kwa-Zulu Natal, Durban, South Africa.
  • Gosnell BI; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Lessells RJ; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Moore PL; South African Medical Research Council, Cape Town, South Africa.
  • de Oliveira T; Africa Health Research Institute, Durban, South Africa.
  • Moosa MS; Division of Infection and Immunity, University College London, London, UK.
  • Sigal A; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Nature ; 607(7918): 356-359, 2022 07.
Article in English | MEDLINE | ID: covidwho-1830078
ABSTRACT
The extent to which Omicron infection1-9, with or without previous vaccination, elicits protection against the previously dominant Delta (B.1.617.2) variant is unclear. Here we measured the neutralization capacity against variants of severe acute respiratory syndrome coronavirus 2 in 39 individuals in South Africa infected with the Omicron sublineage BA.1 starting at a median of 6 (interquartile range 3-9) days post symptom onset and continuing until last follow-up sample available, a median of 23 (interquartile range 19-27) days post symptoms to allow BA.1-elicited neutralizing immunity time to develop. Fifteen participants were vaccinated with Pfizer's BNT162b2 or Johnson & Johnson's Ad26.CoV2.S and had BA.1 breakthrough infections, and 24 were unvaccinated. BA.1 neutralization increased from a geometric mean 50% focus reduction neutralization test titre of 42 at enrolment to 575 at the last follow-up time point (13.6-fold) in vaccinated participants and from 46 to 272 (6.0-fold) in unvaccinated participants. Delta virus neutralization also increased, from 192 to 1,091 (5.7-fold) in vaccinated participants and from 28 to 91 (3.0-fold) in unvaccinated participants. At the last time point, unvaccinated individuals infected with BA.1 had low absolute levels of neutralization for the non-BA.1 viruses and 2.2-fold lower BA.1 neutralization, 12.0-fold lower Delta neutralization, 9.6-fold lower Beta variant neutralization, 17.9-fold lower ancestral virus neutralization and 4.8-fold lower Omicron sublineage BA.2 neutralization relative to vaccinated individuals infected with BA.1. These results indicate that hybrid immunity formed by vaccination and Omicron BA.1 infection should be protective against Delta and other variants. By contrast, infection with Omicron BA.1 alone offers limited cross-protection despite moderate enhancement.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Antibodies, Neutralizing / Cross Protection / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04830-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Antibodies, Neutralizing / Cross Protection / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04830-x